Diffuse malignant peritoneal mesothelioma - An update on treatment

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 605-612

  Mirarabshahii, Peyman ^b,c   Pillai, Krishna ^b,c   Chua, Terence C ^a,b,c   Pourgholami, Mohammad H ^b,c   Morris, David L ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cisplatin; Cytoreductive surgery; Doxorubicin; Hyperthermic intraperitoneal chemotherapy; Malignant peritoneal mesothelioma; Pemetrexed

Indexed keywords

ASBESTOS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; IMMUNOTOXIN; IMMUNOTOXIN SS1P; IRINOTECAN; MELPHALAN; MITOMYCIN C; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RALTITREXED; UNCLASSIFIED DRUG; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DIFFUSE MALIGNANT PERITONEAL MESOTHELIOMA; DRUG EFFECT; DRUG EFFICACY; HUMAN; MALIGNANT MESOTHELIOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PERITONEUM MESOTHELIOMA; PROGNOSIS; REVIEW; SURVIVAL TIME; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HUMANS; MESOTHELIOMA; PERITONEAL NEOPLASMS; PROGNOSIS;

EID: 84861699076     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.10.006     Document Type: Review

References (94)

1. Bridda A., Padoan I., Mencarelli R., Frego M. Peritoneal mesothelioma: a review. Med Gen Med 2007, 9(2):32.
2. Tanida S., Kataoka H., Kubota E., Mori Y., Sasaki M., Ogasawara N. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol 2009, 14(3):266-269.
3. Scripcariu V., Dajbog E., Radu I., Ferariu D., Pricop A., Grigoras M., et al. Malignant peritoneal mesothelioma tumours. Evolution, treatment, prognosis. Rev Med Chir Soc Med Nat Iasi 2007, 111(3):673-677.
4. Souza FF, Jagganathan J, Ramayia N, Johnston C, Jackman D, Abbeele AV, Ros PR. Recurrent malignant peritoneal mesothelioma: radiological manifestations. Abdom Imaging 2009 Mar 25.
5. Moolgavkar S.H., Meza R., Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control 2009, 20(6):935-944.
6. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007, 18(6):985-990.
7. Teoh W.C., Haghighi K.S., Morris D.L. Aggressive multimodality treatment for primary malignant peritoneal mesothelioma. ANZ J Surg 2001, 71(11):683-685.
8. Yan T.D., Popa E., Brun E.A., Cerruto C.A., Sugarbaker P.H. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006, 93(12):1536-1542.
9. Manzini Vde P., Recchia L., Cafferata M., Porta C., Siena S., Giannetta L., et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010, 21(2):348-353.
10. Levy AD, Arnaiz J, Shaw JC, Sobin LH. From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics. 2008;28(2):583-607; quiz 21-2.
11. Hadi R., Saunders V., Utkina O., Clingan P., Kam P., Links M., et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006, 76(3):156-161.
12. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99(2):109-13.
13. Fasola G., Puglisi F., Follador A., Aita M., Di Terlizzi S., Belvedere O. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report. BMC Cancer 2006, 6:289.
14. Carbone M., Ly B.H., Dodson R.F., Pagano I., Morris P.T., Dogan U.A., et al. Malignant mesothelioma: facts, myths and hypotheses. J Cell Physiol 2012, 227(1):44-58.
15. Clin B., Morlais F., Dubois B., Guizard A.V., Desoubeaux N., Marquignon M.F., et al. Occupational asbestos exposure and digestive cancers - a cohort study. Aliment Pharmacol Ther 2009, 30(4):364-374.
16. Chua T.C., Yan T.D., Morris D.L. Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg 2009, 52(1):59-64.
17. Davidson B. New diagnostic and molecular characteristics of malignant mesothelioma. Ultrastruct Pathol. 2008;32(6):227-40.
18. Yan T.D., Welch L., Black D., Sugarbaker P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007, 18(5):827-834.
19. Sethna K., Sugarbaker P.H. Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation. Hepatogastroenterology 2005, 52(64):1087-1089.
20. Serio G., Gentile M., Pennella A., Marzullo A., Buonadonna A.L., Nazzaro P., et al. Characterization of a complex chromosome aberration in two cases of peritoneal mesothelioma arising primarily in the hernial sac. Pathol Int 2009 Jun, 59(6):415-421.
21. Abban C., Viglione M. Peritoneal mesothelioma presenting as a skin nodule. J Cutan Pathol 2009, 36(6):675-679.
22. Pappa L., Machera M., Tsanou E., Damala C., Peschos D., Bafa M., et al. Subcutaneous metastasis of peritoneal mesothelioma diagnosed by fine-needle aspiration. Pathol Oncol Res 2006, 12(4):247-250.
23. de Pangher Manzini V. Malignant peritoneal mesothelioma. Tumori 2005, 91(1):1-5.
24. Comin C.E., Saieva C., Messerini L. H-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007, 31(8):1139-1148.
25. Baratti D., Kusamura S., Martinetti A., Seregni E., Oliva D.G., Laterza B., et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2007, 14(2):500-508.
26. Ishikawa K., Segawa T., Hagiwara Y., Maeda M., Abe M., Hino O. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int 2009, 59(3):161-166.
27. Shiomi K., Hagiwara Y., Sonoue K., Segawa T., Miyashita K., Maeda M., et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008, 14(5):1431-1437.
28. Factor R.E., Dal Cin P., Fletcher J.A., Cibas E.S. Cytogenetics and fluorescence in situ hybridization as adjuncts to cytology in the diagnosis of malignant mesothelioma. Cancer Cytopathol 2009, 117(4):247-253.
29. Chiosea S., Krasinskas A., Cagle P.T., Mitchell K.A., Zander D.S., Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008, 21(6):742-747.
30. Creaney J., Yeoman D., Naumoff L.K., Hof M., Segal A., Musk A.W., et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007, 62(7):569-576.
31. Patel N.P., Taylor C.A., Levine E.A., Trupiano J.K., Geisinger K.R. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol 2007, 128(3):414-422.
32. Husain AN, Colby TV, Ordã3ã±ez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med 2009;133(8):1317-1331.
33. Chua T.C., Yan T.D., Deraco M., Glehen O., Moran B.J., Sugarbaker P.H. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg 2011, 98(1):60-64.
34. Takeuchi N., Nakai M., Sato M. A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma. Gan To Kagaku Ryoho 2008, 35(4):677-681.
35. Yan T.D., Yoo D., Sugarbaker P.H. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006, 32(9):948-953.
36. Muensterer OJ, Averbach AM, Jacquet P, Otero SE, Sugarbaker PH. Malignant peritoneal mesothelioma. Case-report demonstrating pitfalls of diagnostic laparoscopy. Int Surg 1997;82(3):240-243.
37. Yan T.D., Brun E.A., Cerruto C.A., Haveric N., Chang D., Sugarbaker P.H. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007, 14(1):41-49.
38. Sugarbaker P.H. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg 1999, 384(6):576-587.
39. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional databasei. Cancer. 2011;117(9):1855-1863.
40. Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. The British journal of surgery [Multicenter Study]. 2011;98(1):60-64.
41. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol [Multicenter Study]. 2009 20;27(36):6237-6242.
42. Mohamed F., Cecil T., Moran B., Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 2011, 18(2):e84-e96.
43. Stewart JHt, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther [Review]. 2008;8(11):1809-1818.
44. Sugarbaker P.H. Peritonectomy procedures. Cancer Treat Res 1996, 82:235-253.
45. Sugarbaker P.H. Peritonectomy procedures. Ann Surg 1995, 221(1):29-42.
46. Baratti D., Kusamura S., Cabras A.D., Laterza B., Balestra M.R., Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2010, 17(1):45-53.
47. Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23(1):187-190.
48. Sugarbaker P.H. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 2007 Aug, 23(5):431-442.
49. Yan T.D., Stuart O.A., Yoo D., Sugarbaker P.H. Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med 2006, 4:17.
50. Begossi G., Gonzalez-Moreno S., Ortega-Perez G., Fon L.J., Sugarbaker P.H. Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol 2002, 28(1):80-87.
51. Sugarbaker P.H. An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution. J Surg Oncol 2005, 92(2):142-146.
52. Hesdorffer M.E., Chabot J.A., Keohan M.L., Fountain K., Talbot S., Gabay M., et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 2008, 31(1):49-54.
53. Al-Shammaa H.A., Li Y., Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008, 14(8):1159-1166.
54. Khatri V.P. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a panacea or just an obstacle course for the patient?. J Clin Oncol 2010, 28(1):5-7.
55. Gomez Portilla A., Cendoya I., Muriel J., Olabarria I., Guede N., Moraza N., et al. Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia. Cir Esp 2007, 81(2):82-86.
56. Esquivel J., Averbach A. Combined laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a patient with peritoneal mesothelioma. J Laparoendosc Adv Surg Tech A 2009, 19(4):505-507.
57. Van der Speeten K., Stuart O.A., Mahteme H., Sugarbaker P.H. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol 2009, 63(5):799-805.
58. Sugarbaker P.H., Acherman Y.I., Gonzalez-Moreno S., Ortega-Perez G., Stuart O.A., Marchettini P., et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 2002, 29(1):51-61.
59. Mohamed F., Sugarbaker P.H. Peritoneal mesothelioma. Curr Treat Options Oncol 2002, 3(5):375-386.
60. Sugarbaker P.H., Yan T.D., Stuart O.A., Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006, 32(6):686-691.
61. Sugarbaker P.H. Local-regional approach to diffuse malignant peritoneal mesothelioma. Gastroenterol Clin Biol 2007, 31(10):780-781.
62. Cerruto C.A., Brun E.A., Chang D., Sugarbaker P.H. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med 2006, 130(11):1654-1661.
63. Sebbag G., Sugarbaker P.H. Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol 2001, 27(3):223-224.
64. Brouquet A., Goéré D., Lefèvre J.H., Bonnet S., Dumont F., Raynard B., et al. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome. Ann Surg Oncol 2009, 16(10):2744-2751.
65. Sebbag G., Yan H., Shmookler B.M., Chang D., Sugarbaker P.H. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000, 87(11):1587-1593.
66. Chua TC, Liauw W, Morris DL. New treatments and outcomes in peritoneal carcinomatosis. Med J Aust. 2009 Jul 6;191(1):3-4.
67. Gusani N.J., Cho S.W., Colovos C., Seo S., Franko J., Richard S.D., et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008, 15(3):754-763.
68. Yan T.D., Edwards G., Alderman R., Marquardt C.E., Sugarbaker P.H. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma-a prospective study of 70 consecutive cases. Ann Surg Oncol 2007, 14(2):515-525.
69. Chua T.C., Yao P., Akther J., Young L., Bao S., Samaraweera U., et al. Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma. Pathol Oncol Res 2009, 15(4):671-678.
70. Scagliotti G.V., Selvaggi G. Emerging drugs for mesothelioma. Expert Opin Emerg Drugs 2007, 12(1):127-137.
71. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [see comment]. J Clin Oncol 2003;21(14):2636-2644.
72. Jänne P.A., Wozniak A.J., Belani C.P., Keohan M.L., Ross H.J., Polikoff J.A., et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005, 7(1):40-46.
73. Carteni G., Manegold C., Garcia G.M., Siena S., Zielinski C.C., Amadori D., et al. Malignant peritoneal mesothelioma - results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009, 64(2):211-218.
74. Simon G.R., Verschraegen C.F., Janne P.A., Langer C.J., Dowlati A., Gadgeel S.M., et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008, 26(21):3567-3572.
75. Kusama T., Kodaka T., Tsunemine H., Akasaka H., Koizumi N., Fujimoto K., et al. A case of sarcomatoid malignant peritoneal mesothelioma responding to combination chemotherapy of cyclophosphamide, vincristine, adriamycin and dacarbazine(CYVADIC). Gan To Kagaku Ryoho 2009, 36(3):475-478.
76. Lainakis G., Zagouri F., Kastritis E., Sergentanis T.N., Bozas G., Dimopoulos M.A., et al. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Tumori 2011, 97(1):25-29.
77. Molucon-Chabrot C., Isambert N., Benoit L., Zanetta S., Fraisse J., Guilland J.C., et al. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis. Anticancer Drugs 2006, 17(10):1211-1217.
78. Patriti A., Cavazzoni E., Graziosi L., Pisciaroli A., Luzi D., Gulla N., et al. Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech 2008, 18(4):426-428.
79. Garofalo A., Valle M., Garcia J., Sugarbaker P.H. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 2006, 32(6):682-685.
80. Pestieau S.R., Stuart O.A., Sugarbaker P.H. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Eur J Surg Oncol 2000, 26(7):696-700.
81. Takeuchi K., Fujimoto M., Tsujino T., Takeda Y., Yoshida S. Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. Eur J Gynaecol Oncol 2007, 28(4):322-323.
82. Spugnini E.P., Cardillo I., Verdina A., Crispi S., Saviozzi S., Calogero R., et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res 2006, 12(20 Pt 1):6133-6143.
83. Hassan R., Alexander R., Antman K., Boffetta P., Churg A., Coit D., et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol 2006, 17(11):1615-1619.
84. Zaffaroni N., Costa A., Pennati M., De Marco C., Affini E., Madeo M., et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 2007, 29(6):453-466.
85. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther. 2002;1(9):687-694.
86. Hassan R., Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008, 44(1):46-53.
87. Kreitman R.J., Hassan R., Fitzgerald D.J., Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009, 15(16):5274-5279.
88. Baratti D., Kusamura S., Deraco M. Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2009, 35(11):1198-1199.
89. Blackham A.U., Shen P., Stewart J.H., Russell G.B., Levine E.A. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol 2010, 17(10):2720-2727.
90. Yano H., Moran B.J., Cecil T.D., Murphy E.M. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma. Eur J Surg Oncol 2009, 35(9):980-985.
91. Elias D., Bedard V., Bouzid T., Duvillard P., Kohneh-Sharhi N., Raynard B., et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol 2007, 31(10):784-788.
92. Yan T.D., Brun E.A., Cerruto C.A., Haveric N., Chang D., Sugarbaker P.H. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 2007, 14(1):41-49.
93. Brigand C., Monneuse O., Mohamed F., Sayag-Beaujard A.C., Isaac S., Gilly F.N., et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 2006, 13(3):405-412.
94. Feldman A.L., Libutti S.K., Pingpank J.F., Bartlett D.L., Beresnev T.H., Mavroukakis S.M., et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003, 21(24):4560-4567.